.jpg "Rena Xian, MD (she/her/hers) photo")
Rena Xian, MD (she/her/hers)
Associate Professor
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
Description: Assessment of immunoglobulin and T-cell receptor gene rearrangements by next generation sequencing (NGS) methodology is being increasingly applied to evaluate lymphoid clonality, IGH somatic hypermutation in chronic lymphocytic leukemia, clonotype selection for measurable residual disease (MRD) monitoring, and immune repertoire. Specifically for clinical applications, validation-based studies have been published with variable detail regarding case selection, preanalytical factors, validation approach and importantly, criteria for establishing the presence of a clonal lymphoid population. This AMP Clinical Practice Committee Working Group session will provide an update on their efforts to develop recommendations for validation of NGS assays for lymphoid clonality, along with an opportunity to provide feedback to the Working Group.
Learning Objectives:
- Identify sample and template related factors that significantly impact NGS clonality testing and validation (focusing on IGH and TRG)
- Discuss key perspectives on assay design and validation for clonality and derivative assays (e.g., IGH SHM)
- Review essential metrics required for clonal population definition (clonality) and elements needed for informative clinical reports
Working Group Speaker: DAVID VISWANATHA, MD – Mayo Clinic-Rochester
Working Group Panelist: Maria E. Arcila, MD – Memorial Sloan Kettering Cancer Center
Working Group Panelist: Tim C. Greiner, MS, MD – University of Nebraska Medical Center